



The First-in-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results


David A. Sallman¹, Adam S. Asch², Suman Kambhampati³, Monzr M. Al Malki⁴, Joshua F. Zeidner⁵, William Donnellan⁶, Daniel J. Lee⁷, Paresh Vyas⁸, Deepa Jeyakumar⁹, Gabriel N. Mannis¹⁰, Tiffany N. Tanaka¹¹, Wanxing Chai-Ho¹², Richard A. Larson¹³, Andrew R. Whiteley¹⁴, Guido Marcucci¹, Rami S. Komrokji¹, Guillermo Garcia-Manero¹⁵, Joanna Van Elk¹⁶, Ming Lin¹⁶, Roy Maute¹⁶, Jens-Peter Volkmer¹⁶, Chris H. Takimoto¹⁶, Mark P. Chao¹⁶, and Naval G. Daver¹⁵

¹H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; ²Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK; ³HCA Midwest Health at Research Medical Center, Kansas City, MO; ⁴City of Hope, Duarte, CA; ⁵University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; ⁶Tennessee Oncology/Sarah Cannon Research Institute, Nashville, TN; ⁷Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY; ⁸University of Oxford, Oxford, UK; ⁹University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, CA; ¹⁰Stanford University, Stanford, CA; ¹¹Moore's Cancer Center, University of California San Diego, San Diego, CA; ¹²Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA; ¹³Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL; ¹⁴Baylor University Medical Center, Dallas, TX; ¹⁵MD Anderson Cancer Center, Houston, TX; ¹⁶Gilead Sciences, Inc., Foster City, CA




Background

Magrolimab (Formerly 5F9) Is a First-in-Class Macrophage Immune Checkpoint Inhibitor Targeting CD47




Magrolimab Synergizes With Azacitidine to Induce Remissions in AML Xenograft Models




Methods


5F9005 Study Design: Magrolimab in Combination With AZA in AML and MDS



Magrolimab in Combination With AZA is Well Tolerated




On-Target Anemia Is a Pharmacodynamic Effect and Mitigated With a Magrolimab Priming and Maintenance Dosing Regimen




- An initial priming dose mitigates on-target anemia by CD47 blockade, resulting in a transient hemoglobin drop on the first dose (mean decrease of 0.9 g/dL, range +2.5 to -3.7), which returns to baseline
- The majority of patients had significant hemoglobin improvement and decrease in transfusion frequency over time

Neutrophil and Platelet Improvement Is Seen on Magrolimab + AZA Therapy




Results

Magrolimab + AZA Induces High Response Rates in AML



Preliminary Median Overall Survival Is Encouraging in Both TP53 Wild-Type and Mutant Patients



Conclusions

- Magrolimab is a first-in-class antibody targeting the macrophage checkpoint CD47
- Magrolimab is well tolerated with AZA, with no significant immune-related AEs and showing improvement in cytopenias on therapy
- Regardless of TP53-mutation status, encouraging efficacy is observed with magrolimab + AZA in untreated AML patients unfit for intensive chemotherapy
 - All patients had an ORR of 63% and a CR rate 42%, and patients who were TP53 mutant had an ORR of 69% and a CR rate of 45%
- The preliminary median OS in TP53 wild-type (18.9 months) and TP53 mutant (12.9 months) is promising in this treatment setting in terms of historical treatment
- Given the high unmet need in this population, a randomized phase 3 trial of magrolimab + AZA vs venetoclax + AZA or intensive chemotherapy in front-line TP53-mutant AML is currently enrolling (NCT04778397)
- Furthermore, broader development of magrolimab across all mutational subtypes in AML is warranted and ongoing